Evaluation of the antianxiety and antidepressant activities of mosapride in Wistar albino rats.
Animals
Anti-Anxiety Agents
/ pharmacology
Antidepressive Agents
/ pharmacology
Anxiety
/ drug therapy
Behavior, Animal
/ drug effects
Benzamides
/ pharmacology
Depression
/ drug therapy
Disease Models, Animal
Male
Maze Learning
/ drug effects
Morpholines
/ pharmacology
Rats
Rats, Wistar
Stress, Psychological
/ drug therapy
Swimming
/ physiology
5HT agonist
anxiety
depression
mosapride
Journal
Journal of basic and clinical physiology and pharmacology
ISSN: 2191-0286
Titre abrégé: J Basic Clin Physiol Pharmacol
Pays: Germany
ID NLM: 9101750
Informations de publication
Date de publication:
18 Jul 2019
18 Jul 2019
Historique:
received:
24
05
2018
accepted:
15
11
2018
pubmed:
19
7
2019
medline:
7
1
2020
entrez:
19
7
2019
Statut:
epublish
Résumé
Background The 5HT4 receptor agonists are antidepressants with a unique mode of action. Many studies have been done on investigational drugs, and mosapride has been shown to have a 5HT3 antagonistic property. In this study, we assessed the potential anxiolytic and antidepressant effects of mosapride on Wistar albino rats. Methods The rats were randomly assigned to two models containing 4 groups of 6 animals each. In the anxiety model, four groups included 0.5 mL of 0.5% carboxymethyl cellulose (CMC), mosapride 1.5 mg/kg, mosapride 3 mg/kg and diazepam 2 mg/kg. They were dosed for 5 days. On the 3rd day, the elevated plus maze (EPM) was conducted, and on the 5th day, the open field (OF) tests were conducted. In the depression model, four groups included 0.5 mL of 0.5% CMC, mosapride 1.5 mg/kg, mosapride 3 mg/kg and imipramine 30 mg/kg. After 3 days of dosing, the forced swim test (FST) was conducted, followed by a washout period of 1 month. Then, the rats were subjected to chronic unpredictable stress with sucrose preference. Results Compared with the control, the mosapride-treated animals showed significant anxiolytic behavior at both high and low doses in the EPM and OF tests. In the FST, both high and low doses of mosapride reduced immobility. The climbing behavior was prominent at a high dose of mosapride, whereas swimming was prominent at a low dose. In the chronic stress model, both doses of mosapride preserved sucrose preference comparable to imipramine. Conclusion These findings suggest that mosapride has anxiolytic and antidepressant activities at clinically used doses.
Identifiants
pubmed: 31318691
doi: 10.1515/jbcpp-2018-0089
pii: jbcpp-2018-0089
doi:
Substances chimiques
Anti-Anxiety Agents
0
Antidepressive Agents
0
Benzamides
0
Morpholines
0
mosapride
I8MFJ1C0BY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
World Health Organization. Depression and other common mental disorders: global health estimates. World Heal Organ [Internet]. 2017;1–24. Available at: http://apps.who.int/iris/bitstream/10665/254610/1/WHO-MSD-MER-2017.2-eng.pdf. Accessed: 4 July 2017.
Koloski NA, Jones M, Talley NJ. Evidence that independent gut-to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year population-based prospective study. Aliment Pharmacol Ther 2016;44:592–600.
Lucas G, Debonnel G. 5-HT4 receptors exert a frequency-related facilitatory control on dorsal raphé nucleus 5-HT neuronal activity. Eur J Neurosci 2002;16:817–22.
Mendez-David I, David DJ, Darcet F, Wu MV, Kerdine-Römer S, Gardier AM, et al. Rapid Anxiolytic Effects of a 5-HT4 Receptor Agonist Are Mediated by a Neurogenesis-Independent Mechanism. Neuropsychopharmacology 2014;39:1366–78.
Kii Y, Ito T. Drug-induced ventricular tachyarrhythmia in isolated rabbit hearts with atrioventricular block. Pharmacol Toxicol 2002;90:246–53.
Paget GE, Barnes JM. Toxicity tests. In: Lawrence DR B AL, editor. Evaluation of drug activities pharmacometrics. London, New York: Academic Press, 1964:135–65.
Kurt M, Arik AC, Çelik S. The effects of sertraline and fluoxetine on anxiety in the elevated plus-maze test. J Basic Clin Physiol Pharmacol 2000;11:173–80.
Kroczka B, Branski P, Palucha A, Pilc A, Nowak G. Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull 2001;55:297–300.
Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2007;2:322–8.
Jähkel M, Rilke O, Koch R, Oehler J. Open field locomotion and neurotransmission in mice evaluated by principal component factor analysis-effects of housing condition, individual activity disposition and psychotropic drugs. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:61–84.
Lucki I, Dalvi A, Mayorga AJ. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) 2001;155:315–22.
Parihar VK, Hattiangady B, Kuruba R, Shuai B, Shetty AK. Predictable chronic mild stress improves mood, hippocampal neurogenesis and memory. Mol Psychiatry 2011;16:171–83.
Strekalova T, Spanagel R, Bartsch D, Henn FA, Gass P. Stress-Induced anhedonia in mice is associated with deficits in forced swimming and exploration. Neuropsychopharmacology 2004;29:2007–17.
Bockaert J, Claeysen S, Compan V, Dumuis A. 5-HT4 receptors. Curr Drug Targets CNS Neurol Disord 2004;3:39–51.
Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S, et al. Serotonin4 (5-HT4) receptor agonists are putative antidepressants with a rapid onset of action. Neuron 2007;55:712–25.
Pascual-Brazo J, Castro E, Díaz Á, Valdizán EM, Pilar-Cuéllar F, Vidal R, et al. Modulation of neuroplasticity pathways and antidepressant-like behavioural responses following the short-term (3 and 7 days) administration of the 5-HT4 receptor agonist RS67333. Int J Neuropsychopharmacol 2012 2;15:631–43.
Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005;52:90–110.
Kumar B, Kuhad A, Chopra K. Neuropsychopharmacological effect of sesamol in unpredictable chronic mild stress model of depression: behavioral and biochemical evidences. Psychopharmacology (Berl) 2011;214:819–28.
Strekalova T, Gorenkova N, Schunk E, Dolgov O, Bartsch D. Selective effects of citalopram in a mouse model of stress-induced anhedonia with a control for chronic stress. Behav Pharmacol [Internet]. 2006;17:271–87.
Mongeau R, Blier P, De Montigny C. The serotonergic and noradrenergic systems of the hippocampus: Their interactions and the effects of antidepressant treatments. Brain Research Reviews 1997;23:145–95.
Kurhe Y, Mahesh R, Gupta D, Thangaraj D. Effect of (4a) a novel 5-HT3 receptor antagonist on chronic unpredictable mild stress induced depressive-like behavior in mice: an approach using behavioral tests battery. J Basic Clin Physiol Pharmacol 2015;26:25–33.